GE-2270A

Summary

GE-2270A (also known as MDL 62,879) is a naturally occurring thiopeptide antibiotic produced by Planobispora rosea. It exhibits potent activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), by targeting bacterial EF-Tu. It has not advanced to clinical approval, but has served as a scaffold for semi-synthetic derivatives such as LFF571 that have entered clinical investigation.

Mechanism of Action

Inhibits bacterial protein synthesis by binding to elongation factor Tu (EF-Tu), preventing the EF-Tu·GTP·aminoacyl-tRNA ternary complex from interacting with the ribosomal A site, thereby blocking translocation and halting translation.

Routes of Administration

Goals & Uses

• Scaffold for antibiotic drug discoveryDrug DiscoveryHigh
• Treatment of MRSA infectionsAntimicrobialModerate
• Treatment of Clostridioides difficile infectionAntimicrobialLow
• Treatment of Gram-positive bacterial infectionsAntimicrobialModerate

Contraindications

• Gram-negative bacterial infectionsSpectrum LimitationModerate
• Known hypersensitivity to thiopeptide antibioticsAllergyHigh

Adverse Effects

• HepatotoxicityHepaticUnknownLiver injury or dysfunction
• Injection site reactionsLocalUnknown
• Gastrointestinal intoleranceGastrointestinalUnknown

Drug Interactions

• Other EF-Tu targeting agentsLow
• CYP3A4 substratesLow

Population Constraints

• Pediatric patientsAgeRelative
• Patients with hepatic impairmentOrgan FunctionRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo EMA approval; remains a research and preclinical compound.
• United StatesUnapprovedResearch compound only; not approved by FDA. Derivative LFF571 reached Phase II but was not approved.
• United KingdomUnapprovedNo MHRA approval; research use only.

GE-2270A itself has not received regulatory approval in any jurisdiction. It has been primarily used as a research tool and chemical scaffold. Its semi-synthetic derivative LFF571 was evaluated in Phase II clinical trials for Clostridioides difficile infection.

Evidence & Sources

No sources recorded yet.